Endothelial nitric oxide synthase gene polymorphisms and erectile dysfunction in chronic pain

Area of Science:

• Genetics and Urology
• Pharmacogenomics
• Chronic Pain Management

Background:

• Erectile dysfunction (ED) is a common condition, particularly in men with chronic pain.
• The role of genetic factors, specifically endothelial nitric oxide synthase (eNOS) gene polymorphisms, in treatment response is not fully understood.
• Understanding genetic predispositions can personalize andrological treatment strategies.

Purpose of the Study:

• To determine if eNOS gene polymorphisms (T786C, 4VNTR, G894T) affect the response to andrological treatments in Spanish men.
• To identify genetic markers that predict treatment success for erectile dysfunction in this population.

Main Methods:

• Genotyping of eNOS polymorphisms using quantitative polymerase chain reaction (qPCR) with Taqman probes.
• Analysis of treatment response in 105 Spanish males with ED and chronic pain.
• Statistical analysis using R software to correlate genotypes with treatment outcomes.

Main Results:

• A significant improvement in ED was observed in 76% of patients receiving andrological treatment (iPED5, testosterone, or combination).
• Patients with the T786C-CC genotype showed a significantly better response to treatment.
• Multivariate analysis revealed that age, opioid dose, and the T786C-C allele were significant factors influencing ED risk and severity.

Conclusions:

• The T786C polymorphism in the eNOS gene is a major determinant of variable response to iPED5 and testosterone treatments for erectile dysfunction in Spaniards.
• This finding highlights the potential of eNOS genotyping for predicting treatment efficacy in andrological care.